Daily, oral GLP-1 medication reduced episodes of sleep apnea in adults with excess weight
Adults with moderate-to-severe sleep apnea and excess weight had significantly fewer episodes of breathing interruptions while sleeping after taking the daily oral GLP-1 medication orforglipron for one year, compared with adults in the placebo group, according to new, independent, preliminary late-breaking science presented Monday at the American Heart Association's Scientific Sessions 2026 in…
Adults with moderate-to-severe sleep apnea and excess weight experienced fewer breathing interruptions during sleep and improved overall health after taking the daily oral GLP-1 medication orforglipron for one year, according to new research presented at the American Heart Association's Scientific Sessions 2026 in Chicago. Orforglipron showed significant benefits compared to a placebo in reducing sleep apnea severity, blood oxygen levels, body weight, inflammatory markers, and blood pressure.
Participants taking orforglipron also reported better sleep and higher quality of life. The medication was well-tolerated, with common side effects being mild to moderate nausea, diarrhea, and constipation. Orforglipron could potentially serve as a convenient oral option alongside CPAP therapy or for those unable to use it, offering a promising treatment for obstructive sleep apnea in overweight or obese individuals.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
